Skip to content
OpenCapital
Collapse sidebar
Watchlist
Screener
Filings
Earnings
Charts
Collapse sidebar
Screener
Stocks
Royalty Pharma
Business Segments
Products & Services
R&D funding expense, accrued portion
R&D funding expense, accrued portion
Royalty Pharma
·
Products & Services
·
1 segment
Breakdown
Segments
Phase 2b, TEV-408
View metric
Watchlist
Screener
Filings
Earnings
Charts
Quarterly
Annual
TTM
Segment
Q2 '26
Phase 2b, TEV-408
$14.3M
Total
$14.3M
